MA-VERACODE
28.8.2024 13:51:35 CEST | Business Wire | Press release
Veracode, a global leader in application risk management, today announced the appointments of co-founder Chris Wysopal as Chief Security Evangelist and Jens Wessling as Chief Technology Officer (CTO).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240828594728/en/
Chris Wysopal (left) named Chief Security Evangelist and Jens Wessling (right) promoted to Chief Technology Officer (Photo: Business Wire)
Brian Roche, Chief Executive Officer at Veracode, said, "Developers and security teams turn to Veracode to help them build and maintain secure software as the broad adoption of AI increases security debt and exacerbates an unmanageable security backlog. As the leader in application risk management, we have the most effective solution on the market today to secure the software supply chain. Developers face a significant challenge in finding the right security platform among a sea of options, many of which are not equal. Chris Wysopal, a pioneer in the industry, will help us cut through the noise and amplify Veracode's voice and value. Through Chris’ and Jens’ leadership, we will continue to advance our solutions, deliver innovation, educate the market, and further support our customers and partners around the globe.”
As co-founder of Veracode, Wysopal helped shape the application security testing space and will continue to educate and train the wider tech community on cybersecurity best practices. In his new role as Chief Security Evangelist, he will leverage his 25 years’ experience to influence and advocate for Veracode’s products and services, impacting customers, prospects, influencers, analysts and policy makers. As a seasoned cybersecurity expert and trusted voice in the market, he will also spend time mentoring the next generation of cybersecurity professionals.
Wysopal said, "Chief Security Evangelist is a natural evolution of my role and fulfills my passion for ensuring security is at the heart of software development, deployment and maintenance. This is a perfect fit for me as I am passionate about helping security professionals at every level solve their most pressing cybersecurity challenges. I am equally proud to hand over the CTO reigns to Jens, who has a strong track record of driving technical excellence, so Veracode can deliver even more innovation and secure the software supply chain.”
Wessling has been promoted to Chief Technology Officer after serving as Vice President and Chief Architect since he joined the company in March 2024. Wessling came to Veracode with more than 25 years’ experience in cloud computing, data engineering and software development to architect Veracode’s increasingly interconnected solutions. In his new role as CTO, he will define and shape Veracode’s global technology strategy, in addition to leading the company’s research and product security teams.
Wessling said, "I am honored to expand my leadership role at Veracode—a company that has always been at the forefront of software security. Software supply chain security is one of the biggest challenges in cybersecurity, and I look forward to contributing even more as we help organizations build, buy and implement secure software.”
To learn more, watch the interview with Chris and Jens—broadcast live on Thursday August 29, 2024, at 11.30am Eastern Time and available afterward on demand.
About Veracode
Veracode is a global leader in Application Risk Management for the AI era. Powered by trillions of lines of code scans and a proprietary AI-assisted remediation engine, the Veracode platform is trusted by organizations worldwide to build and maintain secure software from code creation to cloud deployment. Thousands of the world’s leading development and security teams use Veracode every second of every day to get accurate, actionable visibility of exploitable risk, achieve real-time vulnerability remediation, and reduce their security debt at scale. Veracode is a multi-award-winning company offering capabilities to secure the entire software development life cycle, including Veracode Fix, Static Analysis, Dynamic Analysis, Software Composition Analysis, Container Security, Application Security Posture Management, and Penetration Testing.
Learn more at www.veracode.com, on the Veracode blog, and on LinkedIn and X.
Copyright © 2024 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240828594728/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom